FreeOx Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$3.23M
- Investors
-
5
FreeOx General Information
Description
Developer of cerebrovascular protective therapies designed to reduce the effects of oxidative stress related to the neurological and cardiovascular systems. The company's drug includes a molecule with neuroprotective properties that has a proven effect in preventing the damage caused by reperfusion after stroke, enabling patients to recover without disabilities.
Contact Information
Website
www.freeoxbiotech.comCorporate Office
- Calle Circunval lació, 69 local
- Sant Climent de Llobregat
- 08849 Barcelona
- Spain
Corporate Office
- Calle Circunval lació, 69 local
- Sant Climent de Llobregat
- 08849 Barcelona
- Spain
FreeOx Timeline
FreeOx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Equity Crowdfunding | 31-Jan-2026 | $3.23M | Completed | Clinical Trials - Phase 3 | ||
| 3. Seed Round | 01-Aug-2024 | Completed | Clinical Trials - Phase 3 | |||
| 2. Angel (individual) | 08-Nov-2018 | $573K | $573K | Completed | Clinical Trials - Phase 3 | |
| 1. Grant | 13-Sep-2018 | $34.7K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
FreeOx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
FreeOx Patents
FreeOx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026104619-A1 | Co-crystals of uric acid for the treatment of neurological diseases | Pending | 14-Nov-2024 | ||
| AU-2025222779-A1 | Crystalline polymorph of uric acid | Pending | 12-Feb-2024 | ||
| WO-2025172340-A1 | Crystalline polymorph of uric acid | Pending | 12-Feb-2024 | ||
| US-20260216068-A1 | Uric acid liposomes | Pending | 29-Oct-2021 | A61K9/127 |
FreeOx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
FreeOx Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CS Group | Corporation | Minority | ||
| NeuroTechnology Investors | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| European Institute of Innovation and Technology | Government |
FreeOx FAQs
-
When was FreeOx founded?
FreeOx was founded in 2017.
-
Where is FreeOx headquartered?
FreeOx is headquartered in Barcelona, Spain.
-
What is the size of FreeOx?
FreeOx has 6 total employees.
-
What industry is FreeOx in?
FreeOx’s primary industry is Drug Discovery.
-
Is FreeOx a private or public company?
FreeOx is a Private company.
-
What is the current valuation of FreeOx?
The current valuation of FreeOx is .
-
What is FreeOx’s current revenue?
The current revenue for FreeOx is .
-
How much funding has FreeOx raised over time?
FreeOx has raised $5.65M.
-
Who are FreeOx’s investors?
CS Group, NeuroTechnology Investors, , , and European Institute of Innovation and Technology have invested in FreeOx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
